India Post, Apollo Cancer Centres Chennai to launch 'Stamp Out Childhood Cancer' campaign

GSK announces positive results from DREAMM-7 head-to-head phase III trial for Blenrep

Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex

DxVx plans to make a license-in agreement of OVM-200

Final stage in licensing OVM-200 from Oxford Vacmedix in the UK

Azelis inks distribution agreement with Beneo in India and Bangladesh

Azelis will be the exclusive distributor for inulin, oligofructose, scFOS, texturized wheat proteins, faba beans, Beta-glucans, meatless solution

Oceanic-AF study stopped early due to lack of efficacy

OCEANIC-AF is one trial which evaluates asundexian versus apixaban in patients with atrial fibrillation at risk for stroke within the overall OCEANIC phase III program

AskBio announces first patient randomized in Phase 1 Trial of AB-1005

Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels

FDA approves Merck’s Keytruda plus chemotherapy as first line treatment for locally advanced Metastatic HER2-Negative Gastric

Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone

Imfinzi plus chemotherapy approved in China as for metastatic biliary tract cancer

Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient

BioPhy launches AI platform to accelerate the drug development market

The company has raised US$4.5 million in funding for its AI operating system

Bayer posts Q3 2023 Group sales Euro 10.34 billion

We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”